FDA Approval of Subcutaneous Ocrevus Highlights Pharma Innovation for Multiple Sclerosis
Friday, 13 September 2024, 08:08
FDA Approval of Subcutaneous Ocrevus
The FDA on Friday approved a new formulation of Roche and Genentech’s blockbuster drug Ocrevus, aimed at treating multiple sclerosis. This innovative subcutaneous form is expected to significantly enhance access to therapy for patients.
Impact on Multiple Sclerosis Treatment
This approval marks a pivotal moment in pharma innovation, enabling patients to receive treatment with greater convenience.
- The new formulation allows for at-home administration.
- Improved patient adherence due to more flexible dosing.
With this decision, Roche and Genentech are poised to expand their impact in the treatment landscape for multiple sclerosis.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.